No Data
No Data
UBS Maintains CureVac(CVAC.US) With Buy Rating, Cuts Target Price to $12
CureVac Analyst Ratings
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating
Shares of Vaccine Stocks Are Trading Lower After CDC Advisers Begins a Review of Vaccine Guidelines and Discussed a More Narrow Use of COVID-19 Booster Shots.
Express News | Shares of Vaccine Stocks Are Trading Lower After CDC Advisers Begins a Review of Vaccine Guidelines and Discussed a More Narrow Use of COVID-19 Booster Shots
BofA Securities Initiates CureVac(CVAC.US) With Sell Rating, Announces Target Price $2.5